Pediatric healthcare provider Pediatrix Medical Group (NYSE: MD) will be reporting results tomorrow before market hours. Here’s what to look for.
Pediatrix Medical Group beat analysts’ revenue expectations by 3.6% last quarter, reporting revenues of $502.4 million, up 1.2% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts’ same-store sales and EPS estimates.
Is Pediatrix Medical Group a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Pediatrix Medical Group’s revenue to decline 8.9% year on year to $451.1 million, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.24 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Pediatrix Medical Group has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Pediatrix Medical Group’s peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. The Ensign Group delivered year-on-year revenue growth of 16.1%, meeting analysts’ expectations, and Alignment Healthcare reported revenues up 47.5%, topping estimates by 4.4%. The Ensign Group’s stock price was unchanged after the resultswhile Alignment Healthcare was down 7%.
Read our full analysis of The Ensign Group’s results here and Alignment Healthcare’s results here.
There has been positive sentiment among investors in the healthcare providers & services segment, with share prices up 4.9% on average over the last month. Pediatrix Medical Group is down 1.5% during the same time and is heading into earnings with an average analyst price target of $18.07 (compared to the current share price of $12.94).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
